Open AccessCorrelation between the International Neuroblastoma Pathology Classification and genomic signature in neuroblastoma
Author(s) -
Nakazawa Atsuko,
Haga Chizuko,
Ohira Miki,
Okita Hajime,
Kamijo Takehiko,
Nakagawara Akira
Publication year - 2015
Publication title -
cancer science
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.035
H-Index - 141
eISSN - 1349-7006
pISSN - 1347-9032
DOI - 10.1111/cas.12665
Subject(s) - neuroblastoma , histology , correlation , medicine , biology , oncology , pathology , genetics , geometry , mathematics , cell culture
The International Neuroblastoma Pathology Classification ( INPC ) has a prognostic impact that distinguishes two categories of neuroblastoma: favorable histology ( FH ) and unfavorable histology ( UH ). We analyzed 92 cases of neuroblastoma with the INPC evaluation and genomic grouping to investigate the correlation between the INPC and genomic signature, together with their prognostic significance. The correlation of UH tumor and partial gains and/or losses ( GGP ), as well as the correlation of FH tumor and whole gains and/or losses ( GGW ), was statistically significant. Both UH and GGP were late‐onset (median age at diagnosis was 36 and 48 months, respectively) and had poor prognosis (overall survival rate [ OS ], 43.1% and 42.4%, respectively). In contrast, both FH and GGW were early‐onset (median age at diagnosis, 4 and 9.5 months, respectively) and had favorable prognosis ( OS , 88.6% and 87.1%, respectively). Unfavorable histology and GGP had significantly inferior OS compared to FH and GGW . Overall survival was not significantly different among the genomic groups in FH ; however, it was inferior in UH with GGP . In UH with a single copy MYCN , genomic subgroups GGP 2s (both 1p and 11q losses) and GGP 3s (partial 11q loss but not 1p loss) indicated significantly poor prognosis compared to GGP 4s (no partial 1p and 11q loss). As INPC and MYCN amplification were found to be the most powerful prognostic biological factors, they should be included with genomic grouping as treatment stratification for patients with UH and single copy of MYCN .